Editorial · 2015 · Open access

The evolution of European Medicines Agency drug approval: the adaptive licensing

Concetta Di Giorgio, Silvia Adami, Alessio Provenzani, S Bianchi, N. D’Alessandro, Piera Polidori

European Journal of Hospital Pharmacy, 23(1), 1–2 · Published 21 August 2015 · DOI 10.1136/ejhpharm-2015-000740

Open PDFView at the publisherCite this paper

In brief

“The evolution of European Medicines Agency drug approval: the adaptive licensing” is an 2015 editorial by Concetta Di Giorgio and 5 co-authors, published in European Journal of Hospital Pharmacy. OpenAlex counts 1 citations as of 19 November 2026. It is open access: the full text is free to read at European Journal of Hospital Pharmacy.

Citations
1
Most cited in
2019 (1)
References
1
Authors
6

Abstract

In March 2014, the European Medicines Agency (EMA) launched a pilot project of ‘adaptive licensing’ to speed up access to drugs in development, in order to respond to unmet medical needs. The project will involve parallel scientific advice from the regulatory agency, pharmaceutical industry, the companies Health Technology Assessment (HTAs) bodies, organisations studying guidelines on clinical treatment and patient associations. The traditional process of drug authorisation is divided into several parts, involving in vitro studies and in vivo studies in animals (preclinical studies), as well as phase 1–3 randomised controlled trials conducted in humans over a predefined period. When authorisation is granted, the drug is intended for a larger population. Some patients, depending on the type of drug, may be entered into register studies and/or followed by other forms of pharmacovigilance studies.1 ,2 According to the adaptive licensing process, however, initial drug authorisation may be granted on the basis of clinical studies involving a limited number of patients and thus is faster than the normal process. After the initial granting of the license, the number of patients treated slowly increases. The latter are enrolled in various forms of observational studies so as to generate information on the effectiveness and adverse effects of the drug in the real … Correspondence to C Di Giorgio, Department of Clinical Pharmacy, Mediterranean Institute for Transplantation and Advanced Specialised Therapies (ISMETT), Palermo 90127, Italy; digiorgio82{at}hotmail.it

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Di Giorgio, C., Adami, S., Provenzani, A., Bianchi, S., D’Alessandro, N., & Polidori, P. (2015). The evolution of European Medicines Agency drug approval: the adaptive licensing. European Journal of Hospital Pharmacy, 23(1), 1–2. https://doi.org/10.1136/ejhpharm-2015-000740

MLA 9

Di Giorgio, Concetta, et al. “The evolution of European Medicines Agency drug approval: the adaptive licensing.” European Journal of Hospital Pharmacy, vol. 23, no. 1, 2015, pp. 1–2. https://doi.org/10.1136/ejhpharm-2015-000740.

Chicago

Di Giorgio, Concetta, Silvia Adami, Alessio Provenzani, S Bianchi, N. D’Alessandro, and Piera Polidori. 2015. “The evolution of European Medicines Agency drug approval: the adaptive licensing.” European Journal of Hospital Pharmacy 23 (1): 1–2. https://doi.org/10.1136/ejhpharm-2015-000740.

Harvard

Di Giorgio, C. et al. (2015) ‘The evolution of European Medicines Agency drug approval: the adaptive licensing’, European Journal of Hospital Pharmacy, 23(1), pp. 1–2. doi:10.1136/ejhpharm-2015-000740.

IEEE

C. Di Giorgio, S. Adami, A. Provenzani, S. Bianchi, N. D’Alessandro, and P. Polidori, “The evolution of European Medicines Agency drug approval: the adaptive licensing,” European Journal of Hospital Pharmacy, vol. 23, no. 1, pp. 1–2, 2015, doi: 10.1136/ejhpharm-2015-000740.

BibTeX

@article{digiorgio2015evolution,
  title     = {{The evolution of European Medicines Agency drug approval: the adaptive licensing}},
  author    = {Di Giorgio, Concetta and Adami, Silvia and Provenzani, Alessio and Bianchi, S and D’Alessandro, N. and Polidori, Piera},
  journal   = {European Journal of Hospital Pharmacy},
  year      = {2015},
  volume    = {23},
  number    = {1},
  pages     = {1--2},
  doi       = {10.1136/ejhpharm-2015-000740},
  url       = {https://doi.org/10.1136/ejhpharm-2015-000740}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy

  • European Medicines Agency
  • drug approval
  • unmet medical needs
  • health technology assessment
  • real-world evidence
  • observational studies
  • pharmacovigilance
  • regulatory process

Work with this paper

Most-cited papers in Economics, Econometrics and Finance

All highly cited Economics, Econometrics and Finance papers

Questions about this paper

How do I cite this paper in APA style?

Di Giorgio, C., Adami, S., Provenzani, A., Bianchi, S., D’Alessandro, N., & Polidori, P. (2015). The evolution of European Medicines Agency drug approval: the adaptive licensing. European Journal of Hospital Pharmacy, 23(1), 1–2. https://doi.org/10.1136/ejhpharm-2015-000740

How many times has this paper been cited?

1 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at European Journal of Hospital Pharmacy: sign in and open the PDF from this page.

Who wrote this paper?

Concetta Di Giorgio, Silvia Adami, Alessio Provenzani, S Bianchi, N. D’Alessandro, Piera Polidori.

What is the DOI of this paper?

10.1136/ejhpharm-2015-000740, permanently at https://doi.org/10.1136/ejhpharm-2015-000740. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.